Novel Radionuclide Agent Delivers "Striking" Results in Neuroendocrine Tumors

Anita T. Shaffer @Shaffer1
Published: Tuesday, Aug 02, 2016
Jonathan R. Strosberg

Jonathan R. Strosberg, MD

Lutathera (lutetium Lu 177 dotatate) has demonstrated “quite striking” results with a favorable safety profile as a therapy for patients with progressive midgut neuroendocrine tumors (NETs) in the first randomized phase III study to evaluate a radiolabeled somatostatin analogue in this treatment setting, according to a leading researcher.

The latest results for the NETTER-1 study, presented at the 2016 World Congress on Gastrointestinal (GI) Cancer, confirm earlier interim findings for the peptide receptor radionuclide therapy, a budding area of oncology research.1

“Based on the survival curves, we’re anticipating a median progression-free survival [PFS] in excess of 3 years,” said Jonathan R. Strosberg, MD, an associate professor at Moffitt Cancer Center, in an interview with OncLive. Strosberg presented the NETTER-1 findings at the World GI conference, which was held in Barcelona in June. Lutathera consists of the somatostatin analog octreotide connected with the beta- and gamma- emitting radiopharmaceutical 177Lutetium (177Lu). The two components are connected using the chelator DOTA.

“The concept is that most well-differentiated neuroendocrine tumors express high levels of somatostatin receptors,” said Strosberg. “We target them with somatostatin analogues but radiolabeled somatostatin analogues are attaching a radioactive isotope to a somatostatin analogue, thereby delivering radiation directly to the tumor cells.”

The drug already is available in the United States under an expanded access program for patients with progressive serious or life-threatening midgut carcinoid tumors who do not have other therapeutic options, Advanced Accelerator Applications, the company developing Lutathera, announced in March. Ten European countries also have approved the drug through compassionate use programs, the company said.

In late June, the FDA granted a priority review designation for Lutathera based on the results of the NETTER-1 trial, setting in motion a decision deadline of December 28, 2016, according to Advanced Accelerator Applications.

Lutathera represents a new generation of radionuclide, a category that consists of compounds that deliver radiation to the tumor target through carriers including liposomes filled with radionuclides, radioactive ions, and radiolabeled antibodies, antibody fragments, peptides, and low molecular weight drugs.2

In oncology, radiopharmaceutical therapies utilized in this class are the radioiodine I-131 in thyroid cancer, neuroblastoma, and non-Hodgkin lymphoma (NHL); the radioisotope yttrium Y-90 in hepatic metastases and NHL; and the radioisotopes strontium-89 and samarium 152 in painful bone metastases.2

Pivotal Trial Details

The NETTER-1 study enrolled patients with inoperable, well-differentiated, somatostatin receptor–positive NETs of the small intestine or distal colon (midgut carcinoid tumors) who had progressed after standard-dose octreotide LAR (30 mg) therapy.

In all, 230 patients were randomized to Lutathera or high-dose octreotide LAR. Four doses of Lutathera were administered at 7.4 GBq every 8 weeks in combination with octreotide at 30 mg for symptom control. In the control arm, patients received octreotide LAR at 60 mg every 4 weeks. The median PFS, the primary endpoint of the study, has not yet been reached with Lutathera compared with 8 months for the control arm, Strosberg said.

“There was a substantially higher response rate with lutetium dotatate—it was 18% versus only 3% with high-dose octreotide,” said Strosberg. “There was a very strong signal suggesting an improvement in overall survival. There were nearly twice as many deaths on the control arm as on the investigational arm, translating to a 60% improvement in overall survival, although this is an interim analysis.”

In terms of safety, Strosberg said the two main concerns with the drug are the risk of renal toxicity and hematotoxicity.

In NETTER-1 trial, however, there was no evidence that Lutathera caused renal toxicity, Strosberg said. In the area of hematotoxicities, there was a 1% to 2% incidence of grade 3-4 neutropenia and thrombocytopenia. Although there was a higher incidence of grade 3-4 lymphopenia, reported at 9% in the conference abstract, these events did not lead to clinically significant effects such as opportunistic infections, Strosberg said.

Strosberg said one of the main problems investigators encountered with Lutathera was nausea and vomiting during amino acid infusions administered concurrently with the study drug to protect the kidneys. He said researchers were required under the study protocol to use a commercial formulation with 18 to 21 amino acids; by contrast, European oncologists have reduced nausea by using a modified regimen with two amino acids.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication